A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(10 sites)

United States

Dana Farber Cancer Institute, Boston, Massachusetts

Mayo Clinic Cancer Center, Rochester, Minnesota

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey

Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities), Commack, New York

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

Ohio State University, Columbus, Ohio